{"organizations": [], "uuid": "f28396f94b437163413f4e2f39e0af81992c2e61", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180122.html", "section_title": "Archive News &amp; Video for Monday, 22 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-regeneron-announces-approval-of-du/brief-regeneron-announces-approval-of-dupixent-in-japan-for-treatment-of-atopic-dermatitis-idUSFWN1PH0FX", "country": "US", "domain_rank": 408, "title": "BRIEF-Regeneron Announces Approval Of Dupixent (Dupilumab) In Japan For Treatment Of Atopic Dermatitis", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.999, "site_type": "news", "published": "2018-01-22T20:07:00.000+02:00", "replies_count": 0, "uuid": "f28396f94b437163413f4e2f39e0af81992c2e61"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-regeneron-announces-approval-of-du/brief-regeneron-announces-approval-of-dupixent-in-japan-for-treatment-of-atopic-dermatitis-idUSFWN1PH0FX", "ord_in_thread": 0, "title": "BRIEF-Regeneron Announces Approval Of Dupixent (Dupilumab) In Japan For Treatment Of Atopic Dermatitis", "locations": [], "entities": {"persons": [{"name": "dupixent", "sentiment": "none"}], "locations": [{"name": "japan", "sentiment": "none"}, {"name": "japan", "sentiment": "none"}], "organizations": [{"name": "regeneron", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "regeneron pharmaceuticals inc", "sentiment": "negative"}, {"name": "sanofi", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "regeneron pharmaceuticals", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 22 (Reuters) - Regeneron Pharmaceuticals Inc:\n* REGENERON ANNOUNCES APPROVAL OF DUPIXENTÂ® (DUPILUMAB) IN JAPAN FOR THE TREATMENT OF ATOPIC DERMATITIS\n* REGENERON PHARMACEUTICALS - DUPIXENT IS BEING JOINTLY DEVELOPED BY CO, SANOFI UNDER A COLLABORATION AGREEMENT, & WILL BE COMMERCIALIZED IN JAPAN BY SANOFI Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-22T20:07:00.000+02:00", "crawled": "2018-01-23T17:48:21.006+02:00", "highlightTitle": ""}